Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Steroid 5-alpha-reductase | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | 3 oxo 5 alpha steroid 4 dehydrogenase, C terminal | 0.0053 | 0.5 | 0.5 |
Giardia lamblia | Synaptic glycoprotein SC2 | 0.0053 | 0.5 | 0.5 |
Entamoeba histolytica | steroid 5-alpha reductase, putative | 0.0053 | 0.5 | 0.5 |
Schistosoma mansoni | synaptic glycoprotein sc2 related | 0.0053 | 0.5 | 0.5 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0053 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0053 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0053 | 0.5 | 0.5 | |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Plasmodium vivax | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0053 | 0.5 | 0.5 |
Entamoeba histolytica | trans-2,3-enoyl-CoA reductase, putative | 0.0053 | 0.5 | 0.5 |
Plasmodium vivax | polyprenol reductase, putative | 0.0053 | 0.5 | 0.5 |
Plasmodium falciparum | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Echinococcus granulosus | synaptic glycoprotein sc2 | 0.0053 | 0.5 | 0.5 |
Entamoeba histolytica | 3-oxo-5-alpha-steroid 4-dehydrogenase domain-containing protein | 0.0053 | 0.5 | 0.5 |
Trypanosoma brucei | 3-oxo-5-alpha-steroid 4-dehydrogenase-like, putative | 0.0053 | 0.5 | 0.5 |
Leishmania major | 3-oxo-5-alpha-steroid 4-dehydrogenase-like protein | 0.0053 | 0.5 | 0.5 |
Brugia malayi | 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Plasmodium falciparum | polyprenol reductase, putative | 0.0053 | 0.5 | 0.5 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0053 | 0.5 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Echinococcus multilocularis | synaptic glycoprotein sc2 | 0.0053 | 0.5 | 0.5 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0053 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.5 | 0.5 |
Schistosoma mansoni | synaptic glycoprotein sc2 related | 0.0053 | 0.5 | 0.5 |
Echinococcus granulosus | 3 oxo 5 alpha steroid 4 dehydrogenase C terminal | 0.0053 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.5 | 0.5 |
Trypanosoma brucei | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 8.8 nM | Inhibitory actitivity against Steroid 5-alpha-reductase in prostates from male rats | ChEMBL. | 7636849 |
IC50 (binding) | = 8.8 nM | Inhibitory actitivity against Steroid 5-alpha-reductase in prostates from male rats | ChEMBL. | 7636849 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.